MUFG Americas Holdings Corp trimmed its position in Shire PLC (NASDAQ:SHPG) by 32.8% in the fourth quarter, Holdings Channel reports. The fund owned 4,874 shares of the biopharmaceutical company’s stock after selling 2,375 shares during the period. MUFG Americas Holdings Corp’s holdings in Shire were worth $756,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. SeaCrest Wealth Management LLC bought a new stake in shares of Shire in the 4th quarter valued at approximately $107,000. BB&T Investment Services Inc. increased its holdings in shares of Shire by 1,672.3% in the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 786 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of Shire in the 3rd quarter valued at approximately $159,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Shire by 277.4% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock valued at $194,000 after acquiring an additional 921 shares during the last quarter. Finally, Regal Investment Advisors LLC bought a new stake in shares of Shire in the 4th quarter valued at approximately $209,000. Institutional investors and hedge funds own 20.74% of the company’s stock.
A number of brokerages have recently weighed in on SHPG. Piper Jaffray Companies reiterated a “hold” rating on shares of Shire in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a report on Wednesday, January 3rd. Liberum Capital reiterated a “hold” rating on shares of Shire in a report on Wednesday, December 20th. Cowen set a $225.00 price target on Shire and gave the company a “buy” rating in a report on Friday, January 5th. Finally, ValuEngine downgraded Shire from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. One analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. Shire presently has an average rating of “Buy” and a consensus price target of $209.23.
Shire (NASDAQ:SHPG) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. Shire had a return on equity of 14.75% and a net margin of 28.17%. The business had revenue of $4.14 billion during the quarter, compared to analyst estimates of $4.01 billion. During the same quarter in the previous year, the firm posted $3.37 EPS. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. equities analysts forecast that Shire PLC will post 15.27 earnings per share for the current fiscal year.
The business also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a dividend of $0.8937 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a yield of 1.33%. This is a positive change from Shire’s previous semiannual dividend of $0.15. Shire’s payout ratio is currently 4.20%.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.